Literature DB >> 17700156

Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation.

Cinthia B Drachenberg1, Hans H Hirsch, John C Papadimitriou, Rainer Gosert, Ravinder K Wali, Raghava Munivenkatappa, Joseph Nogueira, Charles B Cangro, Abdolreza Haririan, Susan Mendley, Emilio Ramos.   

Abstract

BACKGROUND: JC virus (JCV) viruria is more common than BK virus (BKV) viruria in healthy individuals but in kidney transplants (KT), polyomavirus nephropathy (PVAN) is primarily caused by BKV. Few cases of PVAN have been attributed to JCV. Systematic studies on JCV replication in KT are lacking.
METHODS: Out of a cohort of KT patients screened with urine cytology, patients shedding decoy cells were studied (n=103). Molecular studies demonstrated BKV, JCV, or BKV+JCV shedding in 58 (56.3%), 28 (27.2%), and 17 (16.5%), respectively. Biopsy was performed when decoy cells persisted 2 months or serum creatinine increased >20%.
RESULTS: BKV viruria was strongly associated with BKV viremia (93%), PVAN (48%, P=0.01) and graft loss (P=0.03). Higher BKV viremia correlated with graft dysfunction (P=0.01), more advanced histological pattern of PVAN (P<0.0001), and more infected cells in biopsy (P=0.0001). BKV viremia of > or =10,000 copies/mL was significantly associated with histologically confirmed PVAN (P=0.0001). Reduction of immunosuppression lead to disappearance of decoy cells in patients shedding BK (>93%). JCV viruria, was more often asymptomatic (P=0.002) and affected older patients (P=0.02). JCV PVAN was less common (21.4%) and was characterized by sparse cytopathic changes but significant inflammation and fibrosis. JCV viremia was rare (14.2%), transient, and low (mean 2.0E+03/mL). After reduction of immunosuppression decoy cells persisted in >50% of patients with JCV (P=0.0001), but no graft loss occurred. During the period of the current study, the incidence of BKV-PVAN was 5.5% and the incidence of JCV-PVAN was 0.9%.
CONCLUSIONS: The data point to significant differences of BKV and JCV biology regarding replication and disease in KT patients, with important implications for screening and management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700156     DOI: 10.1097/01.tp.0000269706.59977.a5

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  65 in total

1.  Inhibitory interactions between BK and JC virus among kidney transplant recipients.

Authors:  Xingxing S Cheng; Daniel L Bohl; Gregory A Storch; Caroline Ryschkewitsch; Monique Gaudreault-Keener; Eugene O Major; Parmjeet Randhawa; Karen L Hardinger; Daniel C Brennan
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 2.  Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Authors:  A Bellizzi; C Nardis; E Anzivino; D M Rodìo; D Fioriti; M Mischitelli; F Chiarini; V Pietropaolo
Journal:  J Neurovirol       Date:  2012-02       Impact factor: 2.643

3.  Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.

Authors:  Biswa Nath Sharma; Manfred Marschall; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

4.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 5.  Polyomavirus-associated nephropathy.

Authors:  Cristina Costa; Rossana Cavallo
Journal:  World J Transplant       Date:  2012-12-24

6.  Reevaluating and optimizing polyomavirus BK and JC real-time PCR assays to detect rare sequence polymorphisms.

Authors:  A Dumoulin; H H Hirsch
Journal:  J Clin Microbiol       Date:  2011-02-16       Impact factor: 5.948

7.  Multiplex real-time PCR assay for simultaneous quantification of BK polyomavirus, JC polyomavirus, and adenovirus DNA.

Authors:  Yasuhito Funahashi; Seiko Iwata; Yoshinori Ito; Seiji Kojima; Tetsushi Yoshikawa; Ryohei Hattori; Momokazu Gotoh; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  J Clin Microbiol       Date:  2010-01-06       Impact factor: 5.948

8.  Gallic acid-based small-molecule inhibitors of JC and BK polyomaviral infection.

Authors:  Bethany A O'Hara; Chamila Rupasinghe; Achani Yatawara; Gabriel Gaidos; Dale F Mierke; Walter J Atwood
Journal:  Virus Res       Date:  2014-06-21       Impact factor: 3.303

9.  Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells.

Authors:  Aisling S Dugan; Melissa S Maginnis; Joslynn A Jordan; Megan L Gasparovic; Kate Manley; Rebecca Page; Geoffrey Williams; Edith Porter; Bethany A O'Hara; Walter J Atwood
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

10.  Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma.

Authors:  Joseph J Carter; Kelly G Paulson; Greg C Wipf; Danielle Miranda; Margaret M Madeleine; Lisa G Johnson; Bianca D Lemos; Sherry Lee; Ashley H Warcola; Jayasri G Iyer; Paul Nghiem; Denise A Galloway
Journal:  J Natl Cancer Inst       Date:  2009-09-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.